Objective-Proangiogenic effects of mobilized bone marrow-derived stem/progenitor cells are essential for cardiac repair after myocardial infarction. MicroRNAs (miRNA/miR) are key regulators of angiogenesis. We investigated the differential regulation of angio-miRs, that is, miRNAs regulating neovascularization, in mobilized CD34 + progenitor cells obtained from patients with an acute ST-segment-elevation myocardial infarction (STEMI) as compared with those with stable coronary artery disease or healthy subjects.
xperimental studies have demonstrated that administration or endogenous mobilization of bone marrow-derived progenitor cells limit cardiac injury and dysfunction after prolonged myocardial ischemia. 1, 2 There is strong evidence, supporting the notion that vascular and proangiogenic effects of bone marrow-derived mononuclear or CD34 + progenitor cells play an important role in their capacity to ameliorate cardiac dysfunction after myocardial infarction (MI), based on a specific suicide gene approach or by blocking VEGF (vascular endothelial growth factor) by specific antibodies. 3, 4 Moreover, the administration of ex vivo expanded early outgrowth cells or CD34 + progenitor cells increases myocardial neovascularization in the border zone of the infarction and improves left ventricular ejection function after MI. 5, 6 Fazel et al 7 have observed that mobilization of bone marrow-derived progenitor cells after MI was impaired in mice with a mutation of the c-kit receptor, and this was associated with a reduced cardiac neovascularization and more pronounced left ventricular dysfunction. These studies support the notion that endogenous bone marrow-derived progenitor cells are critical for the angiogenic switch in the infarct border zone, that is, the stimulation of cardiac neovascularization and preservation of cardiac function after MI. The proangiogenic capacity of progenitor cells in patients after acute coronary syndrome (ACS) is therefore likely important for their capacity to promote cardiac repair mechanisms. However, the exact molecular mechanisms contributing to the functional activation of progenitor cells mobilized in the context of an ACS remain to be defined.
Notably, microRNAs (miRNAs), small (≈22-nucleotide) noncoding RNAs have been identified as novel regulators of angiogenic processes, progenitor cell differentiation, and in particular cardiovascular cell fate decisions. [8] [9] [10] [11] The crucial role of miRNAs in the cardiovascular system is further supported by the finding that depletion of the miRNA-processing enzyme Dicer leads to embryonic lethality because of defects in vessel formation and cardiac development. 12 The present study was therefore designed to characterize the proangiogenic effects and differential expression of miRNAs regulating angiogenesis in CD34 + progenitor cells of patients with an acute ST-segment-elevation MI (STEMI) as compared with healthy subjects and patients with stable coronary artery disease (sCAD).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Study Population
CD34
+ progenitor cells were isolated prospectively from patients with acute and 5-day-old STEMI, patients with sCAD, and healthy subjects enrolled in the Swiss SPUM-ACS registry (www.spum-acs.ch). All 3 study groups were age and sex matched. The baseline characteristics of the study population are shown in the The proangiogenic capacity of circulating CD34 + progenitor cells obtained from patients with STEMI at different time points after the event was examined and compared with circulating CD34
+ progenitor cells of patients with sCAD and healthy subjects. We observed a significant increase in the proangiogenic capacity of CD34 + progenitor cells in patients with an acute STEMI as compared with patients with sCAD or healthy subjects ( Figure 1A ).
Differential miR-Expression in CD34 +
Progenitor Cells From Patients With STEMI as Compared With sCAD and Healthy Subjects
MiRNAs have been identified as critical regulators of angiogenic pathways. [8] [9] [10] [11] Thus, we performed a polymerase chain reaction-based miRNA array (including 372 miRs) to detect differentially regulated miRNAs in mobilized CD34 + progenitor cells of patients with STEMI as compared with those with sCAD or healthy subjects (Table I in the online-only Data Supplement). Thirty-six miRNAs were significantly deregulated in CD34 + progenitor cells of patients with STEMI as compared with healthy subjects ( Figure II in the online-only Data Supplement). To investigate the proangiogenic function of CD34 + progenitor cells, we selected 2 known angiomiRs, let-7b and miR-378, 11, 13, 14 which were consistently upregulated in both, the real-time polymerase chain reaction screening array and the validation studies (Figure 2A and 2B) , suggesting a potential role of these miRNAs in the regulation of proangiogenic effects of CD34 + progenitor cells. Other miRNAs of the validation studies, which were confirmed to be substantially upregulated in mobilized CD34 + progenitor cells after MI, were members from the miR-181-family, that is, miR-181a, miR-181b, and miR-181d ( Figure 2C through  2E) . Notably, miR-378, miR-181a, miR-181b, and miR-181d were significantly deregulated when compared with not only healthy subjects but also patients with sCAD ( Figure 2A , 2C through 2E). No significant differences between the groups could be confirmed in the validation study for the other miRNAs ( Figure III 
Cells in WST1 Proliferation Assay
It is known that the number of circulating CD34 + progenitor cells is increased in peripheral blood after MI. 15 Therefore, we performed in vitro proliferation experiments with WST1 
Increased Proangiogenic Capacity of miR-let-7b and miR-378 but not of miR181a-Transfected CD34 + Cells in In Vitro Angiogenic Assays and Migration Assays
To determine whether miR-let-7b and miR-378 are regulating the angiogenic capacity of CD34 + progenitor cells, CD34 + cells obtained from healthy subjects were first transfected with the pre-miR or scramble-miR, respectively. The transfection efficiency is shown in Figure V in the online-only In addition, using the endothelial scratch migration assay, we observed that CD34 + cells transfected with pre-miR-378 or pre-miR-let-7b had an increased capacity to stimulate endothelial migration as measured by the endothelial migration index i ( Figure 4B ; Figure VIB in the online-only Data Supplement).
To date, the effects of miR-181a on angiogenesis have not been reported yet. Therefore, we performed angiogenesis tube formation assays in HUVECs transfected with pre-miR-181a and anti-miR-181a to determine its impact on angiogenesis and endothelial cells. Pre-miR-181a-transfected HUVECs showed a significantly decreased tube formation capacity, whereas anti-miR-181a transfection led to an increased tube formation activity ( Figure VIII in the online-only Data Supplement).
In summary, the present findings are compatible with the notion that both miRNAs-let-7b and miR- 
Paracrine Proangiogenic Impact of CD34 + Cells
For a long time, the proangiogenic capacity of CD34 + cells was associated with paracrine cytokine release. 16 In our study, we performed an ELISA-based angiogenic cytokine Bioplexassay with supernatant, collected from transfected CD34 + cells. For PECAM-1 (platelet endothelial cell adhesion molecule), VEGF, leptin, and follistatin, we observed a nonsignificant increase after CD34 + cell transfection with pre-miR-378 or pre-let-7b ( Figure IXa and IXb in the online-only Data Supplement).
Microparticle-mediated transfer of miRNAs between different cell types is a possible mechanism for the paracrine effects. 17 Thus, we performed a coculture assay containing transfected CD34
+ cells and HUVECs, measuring the concentration of selected miRNAs in the supernatant and HUVECs. Our results proofed equal miRNA-secretion of pre-miRtransfected CD34
+ cells ( Figure 5A through 5C), whereas significant miRNA uptake in HUVECs could only be demonstrated for miR-378 and miR-181a, but not for let-7b ( Figure  5D and 5E).
Augmented Angiogenic Capacity of Pre-miR-378-Transfected Cells in In Vivo Angiogenic Experiments: Matrigel Plug Assay and Chorioallantoic Membrane Assay
We focused in our in vivo experiments on the proangiogenic function of miR-378. To characterize the role of miR-378 in CD34 + cells in vivo, we performed Matrigel plug assay with pre-and anti-miR-378-transfected CD34 + cells. Strikingly, pre-miR-378-transfected CD34 + cells significantly increased the amount of blood vessel sprouting in the matrigel plug, compared with scramble, whereas anti-miR-378 transfection resulted in significantly decreased blood vessel sprouting ( Figure 6A) . Notably, let-7b-transfected CD34 + cells did not impact in vivo blood vessel sprouting (Figure X in the onlineonly Data Supplement).
Moreover, similar results for pre-miR-378-transfected CD34 + progenitor cells could be verified by chicken embryo in vivo angiogenesis assay. Increased in vivo blood vessel sprouting was observed after incubation of chorioallantoic membrane with pre-miR-378-transfected CD34 + cells as compared with scrambled-miR-transfected CD34 + cells ( Figure 6B ).
Discussion
We here report that in mobilized CD34 + cells obtained from patients with STEMI miRNAs are differentially regulated. In our polymerase chain reaction-based miRNA-profiling analysis and subsequent validation studies with real-time polymerase chain reaction, we observed a significant upregulation of 2 known angio-miRs, miR-378, and let-7b, in CD34 + progenitor cells obtained from patients with STEMI at the time of presentation, compared with healthy subjects and in addition only for miR-378 compared with sCAD. Especially, we identified miR-378 as critical regulator of the proangiogenic capacity of CD34 + progenitor cells and its stimulatory effects on endothelial cells in vitro and in vivo, whereas let-7b upregulation in CD34 + cells failed to exhibit relevant effects on endothelial cells in vivo.
The CD34 + CD45 + progenitor cells population is also defined as early endothelial progenitor cells or as angiogenic cells. Early endothelial progenitor cells enhance neovascularization indirectly via paracrine effects. 18 Bone marrow-derived CD34 + progenitor cells are mobilized in patients with an acute MI or in response to myocardial ischemia. 15, 19, 20 In this context, the investigated angio-miR-378 proofed to markedly increase CD34 + cell proliferation, as measured by the WST1 reaction. Mobilization of CD34 + progenitor cells from the bone marrow into peripheral blood is associated with acute and chronic preservation of left ventricular function in patients with MI. 19, 21 Therefore, increased CD34 + cell count in response to miR-378-mediated proliferation supports the angiogenic effect of CD34 + cells in the context of an acute MI.
Indeed, several in vitro and in vivo studies have reported a proangiogenic effect of CD34 + cells. 4, 6 In particular, the effects of administration of bone marrow-derived mononuclear cells or CD34
+ progenitor cells on recovery of left ventricular function after experimental MI have recently been related to their proangiogenic effects. 3 Consistently, miRNAs, particularly angio-miRs, have been shown to regulate the proliferation, migration, and angiogenic capacity of endothelial cells. 11, 22 Xing et al 23 demonstrated an increased proliferation and in vitro angiogenesis in mesenchymal cells under hypoxic conditions after miR-378 mimic transfection. The present study further demonstrates a marked proangiogenic activation of CD34 + cells in patients with an acute STEMI and identifies the angio-miRs miR-378 and let7b, which are profoundly upregulated in these cells. To further investigate the functional role of these miRs with regards to proangiogenic capacity, CD34 + cells obtained from healthy subjects were transfected with pre-miR-378 and pre-miR-let7b or scrambled miRs. Elevated expression of miR-378 and let-7b increased the proangiogenic capacity of CD34 + cells in vitro by inducing tube formation. Moreover, transfection of CD34 + progenitor cells with both miRNAs (but not with scrambled miR) increased their stimulatory effect on endothelial cells, that is, endothelial cell migration. Vice versa, downregulation of these angio-miRs using anti-miRs reduced the proangiogenic effects and migration effects of CD34 + progenitor cells.
The regulation of angio-miR expression in CD34 + cells and the mechanism of interaction between endothelial cells and stem/progenitor cells are not fully understood. Recent evidence suggests that CD34 + cells facilitate angiogenesis largely via paracrine effects. 16 Hence, we performed the ELISA-based Bioplex Angiogenic Cytokine assay in supernatant of transfected CD34 + cells to investigate, whether the proangiogenic effects of angio-miRs in CD34
+ cells are based on their paracrine secretion of proangiogenic cytokines. Our results revealed no significant changes, only a trend for increased release of follistatin, PECAM-1, leptin, and VEGF in response to miR-378 or let-7b overexpression. Extracellular miRNAs were identified as a new signaling pathway, which could be selectively exported for cellto-cell communication. 24 These extracellular miRs must be protected against degradation by exonucleases. Therefore, they are included into microparticles such as exosomes, microvesicles, or apoptotic bodies or they are attached to protein complexes like argonaute 2 or lipoprotein-complexes. 17 Sahoo et al 25 have reported that exosomes, secreted by CD34 + cells, improve angiogenesis in vivo and in vitro and that several angio-miRs are enriched in their exosomes. Accordingly, we performed coculturing experiments of transfected CD34 + cells and HUVECs, which revealed that CD34 + cell-released angio-miR-378, but not let-7b, is taken up by HUVECs. Thus, transport of angio-miR-378 by microparticles released from CD34 + cells represents a novel, paracrine mechanism, contributing to their angiogenic effects on endothelial cells by direct endocytosis of the miR-378. These angio-miR-containing microparticles therefore likely represent an important mode of intercellular communication and exchange.
MiR-378 is enriched in CD34 + hematopoietic progenitor cells 26 and has been suggested to promote angiogenesis by + cells on endothelial cell migration capacity was measured using the migration index (8 h after scratch). *P<0.05, **P<0.01, data are mean±SEM.
targeting Suppressor of fused (SuFu) and Fus-1 expression and regulates cell survival.
14 Moreover, nude mice injected with miR-378-transfected cancer cells formed substantially larger blood vessels as compared with GFP (green fluorescent protein)-transfected cells.
14 Furthermore, miR-378 has been reported to promote VEGF expression by competing with miR-125a for the same seed region in the VEGF 3′-untranslated region.
14 Sufu and Fus-1 serve as targets for miR-378 repression. Sufu functions as a negative regulator of Sonic hedgehog (Shh) signaling pathway. Shh promotes vessel formation by inducing expression of angiogenic cytokines, including VEGF and angiopoietin-1 (Ang-1) and -2 (Ang-2). 27 Therefore, miRNA-378 may promote angiogenesis by targeting Sufu and Fus-1, and hence indirectly upregulates angiogenic factors.
Based on the results of the paracrine mechanism-demonstrating experiments, we decided to focus our in vivo studies on miR-378-transfected CD34 + cells, offering the highest impact on paracrine angiogenic cytokine release and on angiomiR-endothelial cell uptake.
Taken together, we transferred our recent findings from in vitro-based assays to in vivo angiogenesis models, such as in vivo matrigel plug assay and chorioallantoic membrane assay. Therefore, miR-378-transfected CD34 + cells significantly increased blood vessel infiltration and blood vessel sprouting, in support of our hypothesis. A limitation of the current miR-mimic experiments is the fact that substantially increased miR-378 levels may overestimate the effects of more moderate changes of this miR in patients with MI.
Urbich et al 28 indicated that CD34 + or CD 133 + EPCs from patients with sCAD show reduced endothelial regenerative function and impaired neovascularization. In line with this, our findings suggest an impaired angiogenic capacity for CD34 + cells in patients with sCAD. In this regard, mobilized and isolated CD34 + cells could be transfected by pre-miR-378 to stimulate its proangiogenic capacity. Using this mechanisms, the augmented proangiogenic capacity of CD34 + cells after STEMI could be transferred to CD34 + cells in patients with sCAD.
Moreover, our findings further indicate that the miR181-family is strongly upregulated in CD34 + progenitor cells of patients with acute STEMI. More recently, it has been suggested that increasing miR-181a levels stimulates deprogramming of lymphatic endothelial cells toward a blood vascular phenotype by targeting Prox1. 29 After MI, the In conclusion, we have identified miR-378 and partly let7b as differentially regulated miRNAs in circulating CD34 + progenitor cells from patients with STEMI, which critically modulate the proangiogenic and paracrine capacity of these cells. Furthermore, we investigated a link between miR-181 family and MI. These findings reveal a novel mechanism contributing to the proangiogenic activation of CD34 + progenitor cells in patients with an acute STEMI. Moreover, a novel use of pre-miR-378-transfected CD34
+ cells in stem cell therapy for patients with sCAD seems possible.
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